NCT00130169View on ClinicalTrials.gov

A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Cancer, Malignant Tumors
Interventions
DRUG

E7974

Maximum Tolerated Dose defined as 0.35 mg/m\^2 administered on Days 1 and 15 only of a 28-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.

Trial Locations (2)

11794

University Hospital Medical Center - SUNY at Stony Brook, Stony Brook

89135

Nevada Cancer Institute, Las Vegas

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00130169 - A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies | Biotech Hunter | Biotech Hunter